Supporting evidence that MTDIA could enhance anticancer effects even in MTAP−/− genotypes is found by comparing tumor growth inhibition by single-agent MTDIA treatment in MTAP+/+ and MTAP−/− lung carcinoma cell lines in vivo (26). This evidence concerns the gene MTAP and lung carcinoma.